Also, Goldman Sachs recently added to the bearish outlook on Moderna, downgrading the stock to Hold and cutting its price target from $99 to $51, citing continued revenue guidance reductions and ...
Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for canceled manufacturing contract. Goldman Sachs US Biotechnology Analyst Salveen ...
Goldman Sachs trims its staff, cutting what it deems to be the underperformers. This year, VPs stand to be big targets, BI ...
Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...
Hedge funds unwound positions in single stocks on Friday at the largest amount in over two years, with some activity ...
Goldman Sachs posted impressive revenue and earnings growth in 2024. The financial services powerhouse is preparing for a more favorable macroeconomic and regulatory backdrop. After the stock’s ...
“S&P 500 annual return dispersion in 2024 rose to 70 percentage points, the highest level outside of recessions since 2007,” David Kostin, strategist at Goldman Sachs ... 20.5 Moderna Inc ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback